D e s i g n
Randomized (allocation concealed*), blinded (patients and outcome assessors),* placebocontrolled trial with 2-year follow-up.
S e t t i n g
A Veterans Affairs medical center in Houston, Texas, USA.
P a t i e n t s
180 patients who were ≤ 75 years of age (mean age 52 y, 93% men), had osteoarthritis of the knee as defined by the American College of Rheumatology, reported at least moderate knee pain (scored ≥ 4 on a visual analog scale of 0 to 10) despite maximal medical treatment for ≥ 6 months, and had not received arthroscopy in the previous 2 years. Exclusion criteria were severity grade ≥ 9 (maximum 12), severe deformity, or serious medical problems. Follow-up was 89% at 1 year and 91% at 2 years.
I n t e r v e n t i o n
After stratification for severity of osteoarthritis, patients were allocated to 1 of 3 groups: lavage (n = 61), debridement (n = 59), or placebo (n = 60). In the lavage group, the joint was lavaged with ≥ 10 L of fluid.
Anything that could be flushed out through arthroscopic cannulas was removed, and unstable meniscal tears were removed. Debridement consisted of lavage with ≥ 10 L of fluid, shaving rough articular cartilage, removing loose debris, and trimming torn or degenerated meniscal fragments. Lavage and debridement were done under general anesthesia with endotracheal intubation. The placebo group received three 1-cm skin incisions under a short-acting tranquilizer and an opioid and spontaneously breathed oxygen-enriched air. 
M a i n o u t c o m e m e a s u r e s

M a i n r e s u l t s
Lavage and debridement did not differ from placebo for pain in the study knee at 1 or 2 years (Table) or for any secondary outcome measure.
C o n c l u s i o n
In patients with osteoarthritis of the knee, arthroscopic surgery did not relieve pain or improve function more than a placebo procedure. 
C o m m e n t a r y
Many surgeons have recognized the uncertainty surrounding the efficacy of arthroscopic lavage and debridement for the painful osteoarthritic knee. Most clinicians, in my experience, have concluded that a randomized controlled trial with a sham placebo might resolve that uncertainty but would probably be unethical. The study by Moseley and colleagues is comprehensively reported and referenced and seems to have been carefully done. The methods used for analysis are appropriate. The study found no evidence that lavage or debridement was superior to placebo in this patient group. Furthermore, the 95% confidence intervals for most comparisons did not include a level considered to constitute the minimal important difference, which instead of being prespecified was calculated post hoc from available literature and trial data.
The argument for ethical approval may have focused around equipoise and patient competence. Primum non nocere ("first, do no harm") is breached by this trial; sham surgery is not a harmless placebo, even though it involved only three 1-cm skin incisions under a light anesthetic regimen. But if the single surgeon who performed all procedures was in a state of individual equipoise (i.e., had a genuine uncertainty about the therapeutic merits of each treatment) and the participants, having signed a declaration accepting the possibility of a sham procedure, were competent, informed, and in equipoise, an acceptable argument for ethical approval might emerge. The fact that 44% of eligible patients declined to participate suggests that the information given was clear enough for them at least; those who chose to participate may have been less informed or driven by altruism.
The fact that so many potential participants declined raises the possibility of selection bias, which may threaten generalizability. The authors note that, compared with those who declined, participants were younger, more likely to be white, and had more severe arthritis. It would have been useful to see follow-up data on those who declined to be randomized but who subsequently had either lavage or debridement. Nevertheless, this study makes a case for questioning the value of arthroscopic lavage and debridement in active men younger than 65 years of age with osteoarthritis of the knee. Pain at 1 y (KSPS) 54.8 48.9 5.9 (−2.0 to 13.8) 51.7 48.9 2.8 (−5.9 to 11.5)
Pain at 2 y (KSPS) 53.7 51.6 2.1 (−6.9 to 11.1) 51.4 51.6 0.2 (−8.8 to 9.2) †KSPS = Knee-Specific Pain Scale (scores 0 to 100 [most severe]). None of the differences is statistically significant.
